yanmar is 1 of 22 high-burden tuberculosis (TB) countries with a high prevalence of multidrug-resistant TB (MDR-TB) (resistant to rifampin and isoniazid) of 5% among new cases and 27% among re-treatment cases in 2013 (1, 2). Rapid detection of drug resistance is essential to effectively manage patients with drug-resistant TB. The National TB Reference Laboratory performs genotypic testing with the Hain GenoType MTBDRplus v1.0 (Hain Lifescience GmbH, Nehren, Germany) and phenotypic drug susceptibility testing (DST) of four first-line drugs, isoniazid, rifampin, ethambutol, and streptomycin. However, second-line drugs or pyrazinamide is currently not performed as part of the routine diagnosis of drug-resistant TB. Therefore, little is known about the prevalence of resistance to amikacin, pyrazinamide, levofloxacin, ethionamide, and cycloserine, the drugs used in the MDR regimen in Myanmar (3).
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To examine drug resistance to second-line agents in Myanmar, we employed whole-genome sequencing (WGS) as the surrogate for phenotypic resistance and sequenced two MDR-TB isolates (M78 and M67) from Yangon, Myanmar. Both isolates are resistant to isoniazid, rifampin, ethambutol, and streptomycin by phenotypic DST. The genomic DNA of these two isolates was sequenced using paired-end 250-bp reads on an Illumina MiSeq (Illumina, Inc., Hayward, CA). A total of 1,070,097 and 1,367,219 paired-end reads from M78 and M67, respectively, were mapped to the M. tuberculosis H37Rv reference genome (accession no. AL123456.3) by BWA (4), yielding about 68ϫ and 87ϫ coverage. Single-nucleotide polymorphism (SNP) analysis was performed using GATK pipeline (5) to identify mutations associated with resistance. Final genome assembly was performed using a combination of tools, including Edena v3 (http://www.genomic.ch /edena.php) and FastaAlternateReferenceMaker (5). Ethical approval for this study was given by the Research and Ethical Committee of the University of Medicine 1, Yangon, Myanmar.
Consistent with phenotypic DST results, we identified mutations associated with resistance to rifampin (S450L in rpoB), isoniazid (S315T in katG), ethambutol (M306V in embB), and streptomycin (K43R in rpsL) in M78. Similarly, H445R in rpoB, S315T in katG, M306I and G406D in embB, and K43R in rpsL were identified in M67. Regarding second-line drug resistance, mutations associated with resistance to fluoroquinolones such as levofloxacin (A90V in gyrA) and aminoglycosides such as amikacin (G1484T in rrs) were identified in M78. Likewise, a G1484T rrs mutation was encountered in M67. Interestingly, heteroresistance to fluoroquinolones was identified at the gyrA gene in M67 with D94A and D94G present at 60% and 37% of total reads correspondingly. The pncA I133L and D12G mutations associated with resistance to pyrazinamide were identified in M78 and M67, respectively. Despite the lack of phenotypic DST results, identification of high-confidence mutations conferring resistance to both fluoroquinolones and aminoglycosides suggested that these strains are highly likely to be XDR isolates. This would also reduce the number of effective drugs to only two (ethionamide and cycloserine) in the standard MDR regimen. This underscores the need to introduce second-line DST in routine diagnosis in Myanmar as described previously (6) to enable construction of effective regimens for treatment of drug-resistant TB patients. Doing so will also allow estimation of the prevalence of extensively drug-resistant TB in the country despite the first reported case in 2007 (7) . Accession number(s). This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession numbers MCQX00000000 (M67) and MCQY00000000 (M78). The versions described in this paper are the first versions.
